vs
Side-by-side financial comparison of LendingClub Corp (LC) and Bio-Techne (TECH). Click either name above to swap in a different company.
Bio-Techne is the larger business by last-quarter revenue ($295.9M vs $252.3M, roughly 1.2× LendingClub Corp). LendingClub Corp runs the higher net margin — 20.5% vs 12.8%, a 7.6% gap on every dollar of revenue. On growth, LendingClub Corp posted the faster year-over-year revenue change (15.9% vs -6.4%). Over the past eight quarters, LendingClub Corp's revenue compounded faster (16.1% CAGR vs 4.2%).
LendingClub Corporation is an American financial services company headquartered in San Francisco, California. It was the first peer-to-peer lender to register its offerings as securities with the Securities and Exchange Commission (SEC), and to offer loan trading on a secondary market. At its height, LendingClub was the world's largest peer-to-peer lending platform. The company reported that $15.98 billion in loans had been originated through its platform up to December 31, 2015.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
LC vs TECH — Head-to-Head
Income Statement — Q1 FY2026 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $252.3M | $295.9M |
| Net Profit | $51.6M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | — | 18.4% |
| Net Margin | 20.5% | 12.8% |
| Revenue YoY | 15.9% | -6.4% |
| Net Profit YoY | 341.0% | 68.3% |
| EPS (diluted) | $0.44 | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $252.3M | — | ||
| Q4 25 | $266.5M | $295.9M | ||
| Q3 25 | $266.2M | — | ||
| Q2 25 | $248.4M | $317.0M | ||
| Q1 25 | $217.7M | $316.2M | ||
| Q4 24 | $217.2M | $297.0M | ||
| Q3 24 | $201.9M | $289.5M | ||
| Q2 24 | $187.2M | $306.1M |
| Q1 26 | $51.6M | — | ||
| Q4 25 | — | $38.0M | ||
| Q3 25 | $44.3M | — | ||
| Q2 25 | $38.2M | $-17.7M | ||
| Q1 25 | $11.7M | $22.6M | ||
| Q4 24 | — | $34.9M | ||
| Q3 24 | $14.5M | $33.6M | ||
| Q2 24 | $14.9M | $40.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% |
| Q1 26 | — | — | ||
| Q4 25 | 18.8% | 18.4% | ||
| Q3 25 | 21.5% | — | ||
| Q2 25 | 21.7% | -7.5% | ||
| Q1 25 | 7.2% | 12.2% | ||
| Q4 24 | 5.1% | 16.0% | ||
| Q3 24 | 8.9% | 13.8% | ||
| Q2 24 | 10.4% | 15.0% |
| Q1 26 | 20.5% | — | ||
| Q4 25 | — | 12.8% | ||
| Q3 25 | 16.6% | — | ||
| Q2 25 | 15.4% | -5.6% | ||
| Q1 25 | 5.4% | 7.1% | ||
| Q4 24 | — | 11.7% | ||
| Q3 24 | 7.2% | 11.6% | ||
| Q2 24 | 8.0% | 13.3% |
| Q1 26 | $0.44 | — | ||
| Q4 25 | $0.36 | $0.24 | ||
| Q3 25 | $0.37 | — | ||
| Q2 25 | $0.33 | $-0.11 | ||
| Q1 25 | $0.10 | $0.14 | ||
| Q4 24 | $0.08 | $0.22 | ||
| Q3 24 | $0.13 | $0.21 | ||
| Q2 24 | $0.13 | $0.26 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $1.5B | $2.0B |
| Total Assets | $11.9B | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | — | $177.5M | ||
| Q3 24 | — | $187.5M | ||
| Q2 24 | — | $152.9M |
| Q1 26 | — | — | ||
| Q4 25 | $0 | $260.0M | ||
| Q3 25 | $0 | — | ||
| Q2 25 | $0 | $346.0M | ||
| Q1 25 | $0 | $330.0M | ||
| Q4 24 | $0 | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M |
| Q1 26 | $1.5B | — | ||
| Q4 25 | $1.5B | $2.0B | ||
| Q3 25 | $1.5B | — | ||
| Q2 25 | $1.4B | $1.9B | ||
| Q1 25 | $1.4B | $2.0B | ||
| Q4 24 | $1.3B | $2.1B | ||
| Q3 24 | $1.3B | $2.1B | ||
| Q2 24 | $1.3B | $2.1B |
| Q1 26 | $11.9B | — | ||
| Q4 25 | $11.6B | $2.5B | ||
| Q3 25 | $11.1B | — | ||
| Q2 25 | $10.8B | $2.6B | ||
| Q1 25 | $10.5B | $2.6B | ||
| Q4 24 | $10.6B | $2.7B | ||
| Q3 24 | $11.0B | $2.7B | ||
| Q2 24 | $9.6B | $2.7B |
| Q1 26 | — | — | ||
| Q4 25 | 0.00× | 0.13× | ||
| Q3 25 | 0.00× | — | ||
| Q2 25 | 0.00× | 0.18× | ||
| Q1 25 | 0.00× | 0.16× | ||
| Q4 24 | 0.00× | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
LC
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
